A Phase 1, First-in-human, Oral Single and Multiple Dose-Escalation, Randomized, Double-blinded, Placebo-controlled Study of SYNB1020 in Healthy Adult Volunteers to Evaluate Safety, Tolerability, Dosing, and Pharmacodynamics

Trial Profile

A Phase 1, First-in-human, Oral Single and Multiple Dose-Escalation, Randomized, Double-blinded, Placebo-controlled Study of SYNB1020 in Healthy Adult Volunteers to Evaluate Safety, Tolerability, Dosing, and Pharmacodynamics

Completed
Phase of Trial: Phase I

Latest Information Update: 27 Apr 2018

At a glance

  • Drugs SYNB 1020 (Primary)
  • Indications Hyperammonaemia; Inborn urea cycle disorders; Liver cirrhosis
  • Focus Adverse reactions; First in man; Proof of concept
  • Sponsors Synlogic
  • Most Recent Events

    • 14 Apr 2018 Results presented at The International Liver Congress 2018
    • 12 Mar 2018 Results published in the Synlogic Media Release
    • 12 Mar 2018 According to a Synlogic media release, data from this trial presented at the 40th Annual Meeting of the Society for Inherited Metabolic Disorders (SIMD) 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top